| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | 20.80 | -65 |
Baxter International Inc. (BTL.DE) is a global leader in healthcare, specializing in a diverse portfolio of medical products and services. Headquartered in Deerfield, Illinois, the company operates in over 100 countries, providing critical healthcare solutions such as dialysis therapies, intravenous treatments, surgical hemostasis products, and connected care technologies. Baxter serves hospitals, dialysis centers, nursing homes, and home healthcare settings, ensuring broad market penetration. The company’s product range includes peritoneal and hemodialysis systems, infusion pumps, anesthesia solutions, and advanced patient monitoring devices. Additionally, Baxter collaborates with pharmaceutical firms through contracted services, enhancing its revenue streams. With a strong focus on innovation, Baxter has strategic partnerships, such as its agreement with Celerity Pharmaceutical to develop acute care injectables. Despite recent financial challenges, including a net loss in the latest fiscal year, Baxter maintains a robust market presence with a €29.6 billion market cap. Its diversified healthcare offerings and global reach position it as a key player in the Medical Instruments & Supplies sector.
Baxter International Inc. presents a mixed investment profile. The company’s diversified healthcare portfolio and global footprint provide stability, but recent financial performance raises concerns, with a net loss of €312 million and negative EPS of -€0.61. However, strong operating cash flow of €1.02 billion and €1.76 billion in cash reserves offer liquidity. Baxter’s low beta (0.61) suggests lower volatility compared to the broader market, appealing to risk-averse investors. The lack of dividends may deter income-focused investors, but potential growth lies in its innovative partnerships and expanding dialysis and critical care segments. High total debt (€13.37 billion) is a risk, but manageable given its cash position. Investors should weigh Baxter’s long-term industry positioning against short-term profitability challenges.
Baxter International Inc. competes in the highly competitive Medical Instruments & Supplies sector, where differentiation through innovation and scale is critical. The company’s strength lies in its comprehensive dialysis and infusion therapy solutions, which are essential in chronic and acute care settings. Baxter’s global distribution network and diversified product portfolio provide a competitive edge, particularly in emerging markets. However, it faces intense competition from larger medtech firms with greater R&D budgets. Baxter’s focus on renal care and critical therapies aligns with growing global healthcare demands, but pricing pressures and regulatory hurdles pose challenges. Its partnership strategy, such as the collaboration with Celerity Pharmaceutical, enhances its pipeline but may not offset competition from rivals with in-house R&D capabilities. While Baxter’s scale ensures market relevance, it must accelerate innovation and cost efficiency to maintain leadership against agile competitors.